Partial Splenic Embolization Is a Safe and Effective Alternative in the Management of Portal Hypertension in Children.


Journal

Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 26 3 2019
medline: 15 9 2020
entrez: 26 3 2019
Statut: ppublish

Résumé

There are multiple approaches to manage the clinical complications of portal hypertension (PHTN) to treat/prevent spontaneous hemorrhage by mitigating thrombocytopenia. No single approach is ideal for all patients given the heterogeneity of this population. Our goal was to determine whether partial splenic embolization (PSE) was safe and effective in the pediatric population. This is a retrospective review of our single-center experience for all patients ages 0 to 21 who underwent PSE between January 2010 and August 2017. The embolized splenic volume targeted was 60% to 70%. Twenty-six patients underwent PSE due to thrombocytopenia and/or recurrent variceal bleeding. Patients ranged in age from 18 months to 20 years (mean 13.1 years). The median platelet count before PSE was 53.0 (×10/L). The platelet count improved after PSE with values >100,000 in 21 patients (80.8%). Children with prior esophageal varices showed improvement after PSE with only 9 (34.6%) requiring further endoscopic therapy. After PSE, patients developed transient abdominal pain, distention, fever, and perisplenic fluid collections. Serious complications such as splenic abscess, splenic rupture, bleeding, pancreatic infarction, opportunistic infection, or death were not observed. One patient experienced thrombotic complications after PSE and was later diagnosed with myelodysplastic syndrome. PSE is a safe and effective alternative in the management of pediatric PHTN in select populations. PSE may be a favorable alternative to splenectomy and portal systemic shunting because it preserves functional spleen mass and avoids postprocedure accelerated liver disease or encephalopathy.

Identifiants

pubmed: 30908386
doi: 10.1097/MPG.0000000000002332
doi:

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

793-798

Auteurs

Jennifer Vittorio (J)

Department of Pediatrics, Columbia University Medical Center, New York, NY.

Katherine Orellana (K)

Department of Pediatrics, Columbia University Medical Center, New York, NY.
Department of Pediatrics, Valley Health System, Ridgewood, NJ.

Mercedes Martinez (M)

Department of Pediatrics, Columbia University Medical Center, New York, NY.

Nadia Ovchinsky (N)

Department of Pediatrics, Columbia University Medical Center, New York, NY.
Department of Pediatrics, Children's Hospital at Montefiore, Bronx.

Peter Schlossberg (P)

Department of Radiology, Columbia University Medical Center.

Adam Griesemer (A)

Department of Surgery, Columbia University Medical Center, New York, NY.

Steven Lobritto (S)

Department of Pediatrics, Columbia University Medical Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH